Market

Market Analysis

The Neuroparticle system will for the first time enable doctors to deliver any form of therapy directly to diseased regions deep in the brain without surgery. There are 50 million patients per year with cancer, neurodegenerative disease, depression, chronic pain, or addiction, the market is in the tens of billions of dollars. Company is targeting the US, Europe and China markets where the image-guided delivery system and the single-use particle dose can generate millions of revenues very soon.

Compact Diagnostic MRI

The first indication for the product will be as a compact diagnostic MRI system, addressing the strong demand for compact MRI systems, which do not require separate rooms, shielding or power.  Hospital, clinic and ER can afford extra diagnostic MRI that will fit within a typical clinical examination room, and that large hospitals may purchase several such systems.

Diagnose and Treat Sinusitis

Chronic Refractory Sinusitis (CRS) possess a large market size as CRS is a common disease, affecting 10% of the US and China, and 100% of certain populations (e.g., cystic fibrosis). At least 25,000 otolaryngologists treat sinusitis in China. There is a long tradition of innovation in minimally invasive methods applied to sinus care, starting with functional endoscopic surgical procedures and proceeding to balloon dilation and placement of drug-eluting expandable wire structures. Our system will enable ENT doctors to break the biofilm and deliver antibiotics directly to sinus.

Treat Brain Tumors

National Brain Tumor Society estimates 700,000 people in the United States are living with a primary brain tumor, and over 86,000 more will be diagnosed in 2019 In China, over 300,000 patients per year present with primary brain tumor. In China, about 50% of the 500,000 patients with lung cancer and 30% of the 170,000 patients with breast cancer develop brain metastases, with median survival of less than two years after diagnosis of the brain metastases.  Patients with leptomeningeal metastases (LM) have poor prognoses (median survival of 4 months) and low quality of life (due to progressive neurologic deficits). LM is particularly difficult to treat when local masses are found adjacent to the spinal cord. Together with our academic partners (University of Illinois at Chicago, Johns Hopkins and Purdue Universities), we have collected preliminary results showing that tumor-killing doses of chemotherapy can be deposited (under real-time imaging guidance) on brain and spinal cord surfaces via magnetically-steered alginate particles.

Deliver Brain Therapy (Non-Cancer)

Company’s long-term goal is to use its technology to serve as a non-invasive alternative to deep brain stimulation (DBS), a technique with rapidly broadening indications that are primarily limited by the invasiveness of the procedure. The number of potential patients in China can be estimated from the prevalence of conditions (for which DBS is currently indicated in the USA or Europe): 500 million with chronic pain, 50 million with substance abuse disorder (including alcohol), 39 million with major depression, 26 million with epilepsy, and 2 million with Parkinson disease. Including the potential for delivery of stem cells or medications for dementia and stroke adds another 10 million people.